Alyeska Investment Group, L.P. Solid Biosciences Inc. Transaction History

Alyeska Investment Group, L.P.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.51 - $7.56 $3.38 Million - $50.1 Million	6,632,978 Added 451.45%	8,102,223 $3.74 Million
Q2 2022 Aug 15, 2022	BUY	$0.43 - $1.24 $64,500 - $186,000	150,000 Added 11.37%	1,469,245 $904,000
Q1 2022 May 16, 2022	BUY	$0.74 - $1.79 $222,000 - $537,000	300,000 Added 29.43%	1,319,245 $1.58 Million
Q4 2021 Feb 14, 2022	BUY	$1.69 - $2.46 $229,143 - $333,546	135,588 Added 15.34%	1,019,245 $1.78 Million
Q3 2021 Nov 15, 2021	BUY	$2.38 - $3.77 $886,592 - $1.4 Million	372,518 Added 72.88%	883,657 $2.11 Million
Q1 2021 May 17, 2021	BUY	$5.37 - $10.72 $2.14 Million - $4.28 Million	399,284 Added 356.97%	511,139 $2.83 Million
Q1 2018 May 15, 2018	BUY	$7.19 - $33.17 $804,237 - $3.71 Million	111,855 New	111,855 $839,000

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $53.2M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Alyeska Investment Group, L.P., based on Form 13F filings with the SEC.

Stay updated on Alyeska Investment Group, L.P. with notifications on news.